X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse JUBILANT LIFE SCIENCES with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 JUBILANT LIFE SCIENCES   ACTAVIS
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
ACTAVIS
Dec-14
JUBILANT LIFE SCIENCES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs18717,672-   
Low Rs6510,779-   
Sales per share (Unadj.) Rs364.33,182.2-  
Earnings per share (Unadj.) Rs6.8-397.1-  
Cash flow per share (Unadj.) Rs24.5292.0-  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %2.40-  
Book value per share (Unadj.) Rs164.96,902.2-  
Shares outstanding (eoy) m159.28265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.5 7.7%   
Avg P/E ratio x18.4-35.8 -51.4%  
P/CF ratio (eoy) x5.148.7 10.6%  
Price / Book Value ratio x0.82.1 37.1%  
Dividend payout %43.80-   
Avg Mkt Cap Rs m20,0613,782,610 0.5%   
No. of employees `0006.221.6 28.6%   
Total wages/salary Rs m11,0520-   
Avg. sales/employee Rs Th9,383.039,173.9 24.0%   
Avg. wages/employee Rs Th1,786.90-   
Avg. net profit/employee Rs Th176.3-4,888.5 -3.6%   
INCOME DATA
Net Sales Rs m58,034846,156 6.9%  
Other income Rs m191-2,112 -9.0%   
Total revenues Rs m58,224844,045 6.9%   
Gross profit Rs m5,786108,701 5.3%  
Depreciation Rs m2,812183,224 1.5%   
Interest Rs m3,23726,689 12.1%   
Profit before tax Rs m-72-103,324 0.1%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,145-7,579 -28.3%   
Tax Rs m696-5,312 -13.1%   
Profit after tax Rs m1,090-105,591 -1.0%  
Gross profit margin %10.012.8 77.6%  
Effective tax rate %-965.95.1 -18,787.6%   
Net profit margin %1.9-12.5 -15.1%  
BALANCE SHEET DATA
Current assets Rs m29,280445,816 6.6%   
Current liabilities Rs m38,912325,131 12.0%   
Net working cap to sales %-16.614.3 -116.4%  
Current ratio x0.81.4 54.9%  
Inventory Days Days8458 145.4%  
Debtors Days Days5166 76.5%  
Net fixed assets Rs m55,712103,324 53.9%   
Share capital Rs m1550-   
"Free" reserves Rs m20,9680-   
Net worth Rs m26,2651,835,282 1.4%   
Long term debt Rs m17,169961,724 1.8%   
Total assets Rs m88,6063,363,468 2.6%  
Interest coverage x1.0-2.9 -34.1%   
Debt to equity ratio x0.70.5 124.7%  
Sales to assets ratio x0.70.3 260.3%   
Return on assets %4.9-2.3 -208.2%  
Return on equity %4.2-5.8 -72.2%  
Return on capital %11.6-3.0 -384.2%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Net fx Rs m10,2550-   
CASH FLOW
From Operations Rs m8,026145,302 5.5%  
From Investments Rs m-1,744-347,907 0.5%  
From Financial Activity Rs m-4,447195,474 -2.3%  
Net Cashflow Rs m1,834-7,132 -25.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare JUBILANT LIFE SCIENCES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare JUBILANT LIFE SCIENCES With: DISHMAN PHARMA  ALKEM LABORATORIES  TTK HEALTHCARE  BIOCON LTD  GLENMARK PHARMA  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views On News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Feb 21, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - DR. REDDYS LAB COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS